Glutoxim solution for injections 1% 1ml. ampoules №5

Description

Glutoxim 1% Storage:

active substance: 1 ml of solution contains glutoxime (glutamyl-cysteinyl-glycine disodium) 10 mg, 30 mg;

Excipients:

sodium acetate, dilute acetic acid, water for injections.

Glutoxim 1% Dosage form.

Solution for injection.

Glutoxim 1% Pharmacotherapeutic group.

Immunostimulants. Cytokines and immunomodulators.

ATC code L03AH.

Clinical characteristics.

Indication.

As a means of prevention and treatment in adults of secondary immunodeficiency conditions associated with radiation, chemical and infectious factors;
to restore suppressed immune reactions and suppressed bone marrow hematopoiesis;
to increase the body’s resistance to various pathological influences – infectious agents, chemical and / or physical factors (intoxication, radiation, etc.);
as a hepatoprotective agent in chronic viral hepatitis B and C;
to potentiate the therapeutic effects of antibacterial therapy of chronic obstructive pulmonary disease;
for the prevention of postoperative purulent complications;
as a part of complex antitubercular therapy of heavy widespread forms of tuberculosis of all localizations;
in the presence of drug resistance of Mycobacterium tuberculosis to drugs;
for the prevention of exacerbations of chronic hepatitis in patients with tuberculosis on the background of anti-tuberculosis therapy;
for the treatment of toxic complications of anti-tuberculosis therapy;
as a part of complex therapy of psoriasis, in particular moderate and severe forms with existence of erythroderma, arthropathy;
as a part of complex therapy of malignant new growths in oncology for prevention and treatment of toxic manifestations of chemotherapy and radiation therapy, namely: promotes decrease in hemo- and hepatotoxic action, promotes effective restoration of functions of bone marrow hematopoiesis at carrying out antitumor therapy. To eliminate the manifestations of nonspecific disease syndrome (anemia, fatigue, decreased appetite, increased pain sensitivity).

Contraindication.

The use of the drug is contraindicated in cases of individual hypersensitivity to the components of the drug.

Method of application and dosage.

The drug Glutoxime is administered intravenously, intramuscularly, subcutaneously. Prescribe daily 5-40 mg (for 1 course – 50-300 mg) depending on the nature of the disease.

For prophylactic purposes, the drug is administered intramuscularly daily at 5-10 mg for 2 weeks.

As part of the complex therapy of tuberculosis Glutoxime 60 mg is administered once a day for the first 10 days daily intramuscularly, the next 20 days Glutoxime 60 mg is administered intramuscularly every other day, one injection per day.

If necessary, repeat the course of treatment in 1-6 months.

As part of the complex therapy of psoriasis Glutoxime is administered intramuscularly daily in a daily dose of 10 mg for 15 days, then for another 5 weeks 2 times a week in a daily dose of 10 mg. A total of 25 injections per course of treatment.

As a means of chemotherapy in oncology Glutoxime 60 mg is administered subcutaneously 1.5-2 hours before the use of anticancer drugs. Then between courses of chemotherapy Glutoxime 60 mg is administered subcutaneously every other day. At the next course of chemotherapy the scheme of drug use is repeated.

As an adjunct to radiation therapy, Glutoxime 60 mg is administered subcutaneously 0.5-1 hour after the next day of irradiation throughout the course of radiation therapy.

Adverse reactions.

In some patients there may be a slight increase in temperature (up to 37.1o C – 37.5o C), soreness at the injection site. In case of poor subjective pain tolerance, Glutoxime is administered together with 1-2 ml of 0.5% solution of novocaine. In such cases, taking into account the information on the safety of novocaine, before using the drug it is necessary to carefully collect an allergy history, to make skin tests for compatibility.

Allergic reactions are possible in predisposed patients.